Abstract Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases,
result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic …

Background Best practice for prevention, diagnosis, and management of venous
thromboembolism (VTE) in patients with coronavirus disease 2019 (COVID‐19) is unknown …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to a worldwide
pandemic, and patients with the infection are referred to as having COVID‐19. Although …

Background A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is
worrying, and the application of heparin in COVID‐19 has been recommended by some …

Background The incidence of venous thromboembolic events (VTE) in patients with COVID-
19 is generally high but varies markedly. However, the relationship between anticoagulation …

Hypercoagulability in coronavirus disease 2019 (COVID-19) may aggravate disease
severity during hospitalization but the reported survival benefits from anticoagulation (AC) …

Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is
commonly complicated with coagulopathy and that disseminated intravascular coagulation …

Abstract Infection with SARS-CoV-2 (COVID-19) can cause prothrombotic complications. We
aim to study the frequency of thrombotic complications and impact of anticoagulation on …

As hospitals worldwide continue to admit an influx of coronavirus disease 2019 (COVID-19)
patients, the puzzling pathogenesis behind the witnessed mortality rates is progressively …

Anticoagulation in Hospitalized Patients with Covid-19 This interactive feature about a man
hospitalized with Covid-19 whose condition is worsening offers a case vignette …